Blinatumomab for paediatric mixed phenotype acute leukaemia

Br J Haematol. 2021 Oct;195(2):289-292. doi: 10.1111/bjh.17707. Epub 2021 Jul 12.
No abstract available

Keywords: immunotherapy; leukaemia; leukaemia therapy; mixed phenotype acute leukaemia; paediatric haematology.

Publication types

  • Case Reports
  • Letter

MeSH terms

  • Aged
  • Antibodies, Bispecific / administration & dosage
  • Antibodies, Bispecific / pharmacology
  • Antibodies, Bispecific / therapeutic use*
  • Antigens, CD19 / drug effects
  • Antigens, CD19 / genetics
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use
  • Combined Modality Therapy / methods
  • Female
  • Hematopoietic Stem Cell Transplantation / methods
  • Histone-Lysine N-Methyltransferase / drug effects
  • Histone-Lysine N-Methyltransferase / genetics
  • Humans
  • Infant
  • Leukemia, Biphenotypic, Acute / drug therapy*
  • Leukemia, Biphenotypic, Acute / genetics
  • Leukemia, Biphenotypic, Acute / pathology
  • Male
  • Myeloid-Lymphoid Leukemia Protein / drug effects
  • Myeloid-Lymphoid Leukemia Protein / genetics
  • Neoplasm, Residual / drug therapy*
  • Neoplasm, Residual / genetics
  • Neoplasm, Residual / pathology
  • Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / drug therapy*
  • Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / genetics
  • Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / pathology
  • Progression-Free Survival
  • Remission Induction
  • Treatment Outcome

Substances

  • Antibodies, Bispecific
  • Antigens, CD19
  • CD19 molecule, human
  • KMT2A protein, human
  • Myeloid-Lymphoid Leukemia Protein
  • blinatumomab
  • Histone-Lysine N-Methyltransferase